Patent 9950125 was granted and assigned to Antares Pharma Inc. on April, 2018 by the United States Patent and Trademark Office.
The present invention provides compositions and methods for treating a subject in need of treatment with testosterone, including introducing testosterone into the subject subcutaneously, intradermally, or intramuscularly, from a needle assisted jet injection device.